Study Finds Daily Aspirin May Not Reduce Risk of Cognitive Decline
Previous research had suggested that taking an aspirin a day may help reduce the risk of dementia due to its’ anti-inflammatory properties. However, a new study has found that taking a low-dose aspirin daily does not decrease the risk of dementia, mild cognitive impairment, or cognitive decline.
Study participants included 19,114 people who were 70 or older and did not have dementia or heart disease at the beginning of the study. Half the participants took a 100 mg aspirin daily and the other half took a placebo for 4.7 years. The researchers used The Modified Mini-Mental State Examination, Hopkins Verbal Learning Test–Revised, Symbol Digit Modalities Test, and Controlled Oral Word Association Test to assess cognitive function at baseline and at annual follow-up examinations.
At the end of the study period, 488 participants in the aspirin group had reached the dementia trigger criteria, compared to 476 participants in the placebo group. The type of dementia trigger was similar between the two groups. The rates of incidence dementia and incident mild cognitive impairment were nearly the same in both groups.
The study was conducted by researchers from Monash University. It was published online ahead of print on March 25, 2020 in the journal Neurology.